Take 2: Abingworth/Clarus launch second Phase III partnering firm Avillion
This article was originally published in Scrip
A new company focused on financing and managing Phase III development and regulatory approval projects on behalf of industry partners has been launched with initial funding from investment partners Abingworth and Clarus Ventures. Based in London, Avillion will be a virtual company relying on the depth of expertise of its senior management team to conduct late-stage programmes that it will license in from major companies in the US and Europe.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.